Long-term outcome of GIST patients treated with delayed imatinib therapy

Eur J Cancer. 2017 Jun:78:118-121. doi: 10.1016/j.ejca.2017.03.024. Epub 2017 Apr 21.

¹ Department of Pathology, Cytology and Human Genetics, Clinical Center of the University of Sarajevo, Sarajevo, Bosnia and Herzegovina; Department of Genetics, Section of Biology, Faculty of Natural Sciences and Mathematics, University of Sarajevo, Sarajevo, Bosnia and Herzegovina. Electronic address: amina.kozaric@kcus.ba.
² Department of Genetics, Section of Biology, Faculty of Natural Sciences and Mathematics, University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
³ Department of Oncology, Clinical Center of the University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
⁴ Department of Pathology, Cytology and Human Genetics, Clinical Center of the University of Sarajevo, Sarajevo, Bosnia and Herzegovina.
⁵ Oncology Clinic, University Clinical Center Tuzla, Tuzla, Bosnia and Herzegovina.
⁶ Department of Pathology, University Clinical Center Tuzla, Tuzla, Bosnia and Herzegovina.
⁷ Department of Pathology, Cytology and Forensic Medicine, University Clinical Hospital Mostar, Mostar, Bosnia and Herzegovina.
⁸ Department of Genetics and Bioengineering, International Burch University, Sarajevo, Bosnia and Herzegovina.
⁹ Hematology Clinic, Clinical Center of the University of Sarajevo, Sarajevo, Bosnia and Herzegovina.

No abstract available

Keywords: Developing country; Gastrointestinal stromal tumour (GIST); Imatinib; Outcome; Targeted therapy.

Publication types